These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31166206)

  • 1. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
    Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
    Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
    Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
    BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
    Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
    Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
    de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
    Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database.
    Achilli P; Crippa J; Grass F; Mathis KL; D'Angelo AD; Abd El Aziz MA; Day CN; Harmsen WS; Larson DW
    Int J Cancer; 2021 Jan; 148(1):161-169. PubMed ID: 32638371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
    Oh SY; Kim DY; Kim YB; Suh KW
    World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
    Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
    Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
    Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
    Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
    Donada M; Bonin S; Nardon E; De Pellegrin A; Decorti G; Stanta G
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):201-10. PubMed ID: 20387074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
    Zaanan A; Taieb J
    Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection.
    Sato C; Kawakami H; Tanaka R; Satake H; Inoue K; Kimura Y; Fujita J; Kawabata R; Chiba Y; Satoh T; Nakagawa K
    Sci Rep; 2023 Jul; 13(1):10826. PubMed ID: 37402831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
    Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
    Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.